Pathfinder Cell Therapy (OTCMKTS:PFND) & CervoMed (NASDAQ:CRVO) Head-To-Head Survey

Pathfinder Cell Therapy (OTCMKTS:PFND) and CervoMed (NASDAQ:CRVO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Institutional and Insider Ownership

25.2% of CervoMed shares are held by institutional investors. 15.1% of Pathfinder Cell Therapy shares are held by company insiders. Comparatively, 35.4% of CervoMed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Pathfinder Cell Therapy and CervoMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pathfinder Cell Therapy	N/A	N/A	N/A
CervoMed	-672.80%	-136.08%	-112.62%

Earnings and Valuation

This table compares Pathfinder Cell Therapy and CervoMed”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A
CervoMed	$4.01 million	6.93	-$26.97 million	($3.28)	-0.91

Pathfinder Cell Therapy has higher earnings, but lower revenue than CervoMed.

Analyst Ratings

This is a summary of current recommendations and price targets for Pathfinder Cell Therapy and CervoMed, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pathfinder Cell Therapy	0	0	0	0	0.00
CervoMed	1	1	6	0	2.63

CervoMed has a consensus target price of $22.60, suggesting a potential upside of 653.33%. Given CervoMed’s stronger consensus rating and higher probable upside, analysts clearly believe CervoMed is more favorable than Pathfinder Cell Therapy.

Summary

CervoMed beats Pathfinder Cell Therapy on 6 of the 9 factors compared between the two stocks.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.

About CervoMed

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.